These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants. Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009 [TBL] [Abstract][Full Text] [Related]
23. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817 [TBL] [Abstract][Full Text] [Related]
24. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792 [TBL] [Abstract][Full Text] [Related]
26. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. van Waalwijk van Doorn LJ; Gispert JD; Kuiperij HB; Claassen JA; Arighi A; Baldeiras I; Blennow K; Bozzali M; Castelo-Branco M; Cavedo E; Emek-Savaş DD; Eren E; Eusebi P; Farotti L; Fenoglio C; Ormaechea JF; Freund-Levi Y; Frisoni GB; Galimberti D; Genc S; Greco V; Hampel H; Herukka SK; Liu Y; Lladó A; Lleó A; Nobili FM; Oguz KK; Parnetti L; Pereira J; Picco A; Pikkarainen M; de Oliveira CR; Saka E; Salvadori N; Sanchez-Valle R; Santana I; Scarpini E; Scheltens P; Soininen H; Tarducci R; Teunissen C; Tsolaki M; Urbani A; Vilaplana E; Visser PJ; Wallin AK; Yener G; Molinuevo JL; Meulenbroek O; Verbeek MM J Alzheimers Dis; 2017; 56(2):543-555. PubMed ID: 28059783 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838 [TBL] [Abstract][Full Text] [Related]
28. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease. Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384 [TBL] [Abstract][Full Text] [Related]
29. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009 [TBL] [Abstract][Full Text] [Related]
31. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease. Modeste ES; Ping L; Watson CM; Duong DM; Dammer EB; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT Mol Neurodegener; 2023 Jul; 18(1):48. PubMed ID: 37468915 [TBL] [Abstract][Full Text] [Related]
32. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Heywood WE; Galimberti D; Bliss E; Sirka E; Paterson RW; Magdalinou NK; Carecchio M; Reid E; Heslegrave A; Fenoglio C; Scarpini E; Schott JM; Fox NC; Hardy J; Bhatia K; Heales S; Sebire NJ; Zetterberg H; Mills K Mol Neurodegener; 2015 Dec; 10():64. PubMed ID: 26627638 [TBL] [Abstract][Full Text] [Related]
33. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736 [TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
35. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. Vafadar-Isfahani B; Ball G; Coveney C; Lemetre C; Boocock D; Minthon L; Hansson O; Miles AK; Janciauskiene SM; Warden D; Smith AD; Wilcock G; Kalsheker N; Rees R; Matharoo-Ball B; Morgan K J Alzheimers Dis; 2012; 28(3):625-36. PubMed ID: 22045497 [TBL] [Abstract][Full Text] [Related]
36. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India. Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261 [TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. Marksteiner J; Hinterhuber H; Humpel C Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711 [TBL] [Abstract][Full Text] [Related]
38. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease. Jingami N; Asada-Utsugi M; Uemura K; Noto R; Takahashi M; Ozaki A; Kihara T; Kageyama T; Takahashi R; Shimohama S; Kinoshita A J Alzheimers Dis; 2015; 45(1):109-15. PubMed ID: 25428256 [TBL] [Abstract][Full Text] [Related]
39. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort. Wang ML; Wei XE; Yu MM; Li PY; Li WB; Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050 [TBL] [Abstract][Full Text] [Related]